Patented technology applied in SynGEM, a needle-free nasal spray vaccine against respiratory syncytial virus * Re-Issuance of U.S. Patent...

#ReSViNET , the Respiratory Syncytial Virus Network, selected the recent publication in AJRCCM on the SynGEM Phase I clinical trial as...

SynGEM a needle-free nasal spray vaccine against respiratory syncytial virus * SynGEM shown to be safe and immunogenic in healthy adults...

A new publication in the American Journal of Respiratory and Critical Care Medicine, headed by senior author prof. Louis Bont of UMC...

Today phase I clinical trial data of the Mucosis intranasal RSV F protein vaccine were published on-line. The vaccine was shown to be...

Virtuvax consults in vaccine development and provides biosimilar and vaccine technologies. A most recent one, is the prefusion RSV-F...

Virtuvax will attend Bionnale 2017, 16 & 17th May 2017 in Berlin Germany. You can meet us there, discuss matchmaking and/or other...

21st and 22nd February our team will be present in Paris at the scientific community meeting of CEPI in which the urgency for action and...

Read the article written by Louis Garguilo of Outsourced Pharma about innovation in the vaccine industry and the role of our company...

Virtuvax will attend the BioWin Day 2016, 8th December 2016 in Louvain-la-Neuve in Belgium. You can meet us there, discuss matchmaking...